Advanced search
1 file | 2.35 MB Add to list

Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease

(2010) CELL. 141(1). p.178-190
Author
Organization
Abstract
Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies.
Keywords
HYPOXIA, LUNG, HEPATOCELLULAR-CARCINOMA, PLACENTA GROWTH-FACTOR, PATHOLOGICAL CONDITIONS, MOUSE MODEL, METASTASIS, ANGIOGENESIS, PROGRESSION, MICE

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 2.35 MB

Citation

Please use this url to cite or link to this publication:

MLA
Van de Veire, Sara, et al. “Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease.” CELL, vol. 141, no. 1, 2010, pp. 178–90, doi:10.1016/j.cell.2010.02.039.
APA
Van de Veire, S., Stalmans, I., Heindryckx, F., Oura, H., Tijeras-Raballand, A., Schmidt, T., … Carmeliet, P. (2010). Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. CELL, 141(1), 178–190. https://doi.org/10.1016/j.cell.2010.02.039
Chicago author-date
Van de Veire, Sara, Ingeborg Stalmans, Femke Heindryckx, Hajimu Oura, Annemilai Tijeras-Raballand, Thomas Schmidt, Sonja Loges, et al. 2010. “Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease.” CELL 141 (1): 178–90. https://doi.org/10.1016/j.cell.2010.02.039.
Chicago author-date (all authors)
Van de Veire, Sara, Ingeborg Stalmans, Femke Heindryckx, Hajimu Oura, Annemilai Tijeras-Raballand, Thomas Schmidt, Sonja Loges, Imke Albrecht, Bart Jonckx, Stefan Vinckier, Christophe Van Steenkiste, Sonia Tugues, Charlotte Rolny, Maria De Mol, Daniela Dettori, Patricia Hainaud, Lieve Coenegrachts, Jean-Olivier Contreres, Tine Van Bergen, Henar Cuervo, Wei-Hong Xiao, Carole Le Henaff, Ian Buysschaert, Bezad Kharabi Masouleh, Anja Geerts, Tibor Schomber, Philippe Bonnin, Vincent Lambert, Jurgen Haustraete, Serena Zacchigna, Jean-Marie Rakic, Wladimiro Jimenez, Agnes Noel, Mauro Giacca, Isabelle Colle, Jean-Michel Foidart, Gerard Tobelem, Manuel Morales-Ruiz, Jose Vilar, Patrick Maxwell, Stanley A Vinores, Geert Carmeliet, Mieke Dewerchin, Lena Claesson-Welsh, Evelyne Dupuy, Hans Van Vlierberghe, Gerhard Christofori, Massimiliano Mazzone, Michael Detmar, Desire Collen, and Peter Carmeliet. 2010. “Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease.” CELL 141 (1): 178–190. doi:10.1016/j.cell.2010.02.039.
Vancouver
1.
Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T, et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. CELL. 2010;141(1):178–90.
IEEE
[1]
S. Van de Veire et al., “Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease,” CELL, vol. 141, no. 1, pp. 178–190, 2010.
@article{931075,
  abstract     = {{Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies.}},
  author       = {{Van de Veire, Sara and Stalmans, Ingeborg and Heindryckx, Femke and Oura, Hajimu and Tijeras-Raballand, Annemilai and Schmidt, Thomas and Loges, Sonja and Albrecht, Imke and Jonckx, Bart and Vinckier, Stefan and Van Steenkiste, Christophe and Tugues, Sonia and Rolny, Charlotte and De Mol, Maria and Dettori, Daniela and Hainaud, Patricia and Coenegrachts, Lieve and Contreres, Jean-Olivier and Van Bergen, Tine and Cuervo, Henar and Xiao, Wei-Hong and Le Henaff, Carole and Buysschaert, Ian and Masouleh, Bezad Kharabi and Geerts, Anja and Schomber, Tibor and Bonnin, Philippe and Lambert, Vincent and Haustraete, Jurgen and Zacchigna, Serena and Rakic, Jean-Marie and Jimenez, Wladimiro and Noel, Agnes and Giacca, Mauro and Colle, Isabelle and Foidart, Jean-Michel and Tobelem, Gerard and Morales-Ruiz, Manuel and Vilar, Jose and Maxwell, Patrick and Vinores, Stanley A and Carmeliet, Geert and Dewerchin, Mieke and Claesson-Welsh, Lena and Dupuy, Evelyne and Van Vlierberghe, Hans and Christofori, Gerhard and Mazzone, Massimiliano and Detmar, Michael and Collen, Desire and Carmeliet, Peter}},
  issn         = {{0092-8674}},
  journal      = {{CELL}},
  keywords     = {{HYPOXIA,LUNG,HEPATOCELLULAR-CARCINOMA,PLACENTA GROWTH-FACTOR,PATHOLOGICAL CONDITIONS,MOUSE MODEL,METASTASIS,ANGIOGENESIS,PROGRESSION,MICE}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{178--190}},
  title        = {{Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease}},
  url          = {{http://doi.org/10.1016/j.cell.2010.02.039}},
  volume       = {{141}},
  year         = {{2010}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: